21 results on '"Xiao, Chu"'
Search Results
2. Primary pulmonary hyalinizing clear cell carcinoma with fusions of both EWSR1::CREM and IRF2::NTRK3: report of a case with an aggressive behavior
- Author
-
You-Li Wu, Feng Wu, Mian-Fu Cao, Yang Lan, Ming-Shan Du, Song-Tao Yu, Yan Wang, Xiao-Chu Yan, Xiu-Wu Bian, and Guang-Jie Duan
- Subjects
hyalinizing clear cell carcinoma ,lung biopsy ,EWSR1::CREM fusion ,next-generation sequencing ,prognosis ,Neoplasms. Tumors. Oncology. Including cancer and carcinogens ,RC254-282 - Abstract
Primary pulmonary hyalinizing clear cell carcinoma (HCCC) is a rare salivary gland-type tumor newly recognized in recent years, with approximately 21 cases reported to date in the English literature, which constitutes a challenge in pathology diagnosis, particularly in small biopsy specimens. Here, we present a case of pulmonary HCCC diagnosed by computed tomography-guided percutaneous lung biopsy in a 70-year-old man’s right lower lung. Although the morphology and immunophenotype of the tumor suggested the diagnosis of mucoepidermoid carcinoma, fluorescence in situ hybridization failed to reveal the rearrangement of MAML2 gene, which is characteristic of mucoepidermoid carcinoma. Instead, further molecular genetic testing showed that the tumor harbored a rare EWSR1::CREM fusion combined with a previously unreported IRF2::NTRK3 fusion. Pulmonary HCCC is commonly regarded as a low-grade malignant tumor with an indolent course, but this case has a different biological behavior, presenting extensive dissemination and metastases at the time of diagnosis, which expands our understanding of the prognosis of this tumor. The patient has had five cycles of combination chemotherapy and has been alive with the tumor for eight months.
- Published
- 2023
- Full Text
- View/download PDF
3. A prognostic risk model based on DNA methylation levels of genes and lncRNAs in lung squamous cell carcinoma
- Author
-
Weiqing Wang, Ming Xiang, Hui Liu, Xiao Chu, Zhaoyun Sun, and Liang Feng
- Subjects
Coronavirus disease 2019 ,Lung squamous cell carcinoma ,Recurrence-free survival ,Prognosis ,DNA methylation ,Medicine ,Biology (General) ,QH301-705.5 - Abstract
Background Recurrence is a risk factor for the prognosis of lung squamous carcinoma (LUSC). DNA methylation levels of RNAs are also associated with LUSC prognosis. This study aimed to construct a prognostic model with high performance in predicting LUSC prognosis using the methylation levels of lncRNAs and genes. Methods The differentially expressed RNAs (DERs) and differentially methylated RNAs (DMRs) between the recurrent and non-recurrent LUSC tissues in The Cancer Genome Atlas (TCGA; training dataset) were identified. Weighted correlation network analysis was performed to identify co-methylation networks. Differentially methylated genes and lncRNAs with opposite expression-methylation levels were used for the screening of prognosis-associated RNAs. The prognostic model was constructed and its performance was validated in the GSE39279 dataset. Results A total of 664 DERs and 981 DMRs (including 972 genes) in recurrent LUSC tissues were identified. Three co-methylation modules, including 226 differentially methylated genes, were significantly associated with LUSC. Among prognosis-associated RNAs, 18 DERs/DMRs with opposite methylation-expression levels were included in the methylation prognostic risk model. LUSC patients with high risk scores had a poor prognosis compared with patients who had low risk scores (TCGA: HR = 3.856, 95% CI [2.297–6.471]; GSE39279: HR = 3.040, 95% CI [1.435–6.437]). This model had a high accuracy in predicting the prognosis (AUC = 0.903 and 0.800, respectively), equivalent to the nomogram model inclusive of clinical variables. Conclusions Referring to the methylation levels of the 16-RNAs might help to predict the survival outcomes in LUSC.
- Published
- 2022
- Full Text
- View/download PDF
4. Identification of DNA repair-related genes predicting pathogenesis and prognosis for liver cancer
- Author
-
Wenjing Zhu, Qiliang Zhang, Min Liu, Meixing Yan, Xiao Chu, and Yongchun Li
- Subjects
Liver cancer ,mRNA ,Biomarker ,Prognosis ,TCGA ,Neoplasms. Tumors. Oncology. Including cancer and carcinogens ,RC254-282 ,Cytology ,QH573-671 - Abstract
Abstract Background Liver cancer (LC) is one of the most fatal cancers throughout the world. More efficient and sensitive gene signatures that could accurately predict survival in LC patients are vitally needed to promote a better individualized and effective treatment. Material/methods 422 LC and adjacent normal tissues with both RNA-Seq and clinical data in TCGA were embedded in our study. Gene set enrichment analysis (GSEA) was applied to identify genes and hallmark gene sets that are more valuable for liver cancer therapy. Cox regression analysis was used to identify genes related to overall survival (OS) and build the prediction model. cBioPortal database was used to examine the alterations of the panel mRNA signature. ROC curves and Kaplan–Meier curves were used to validate the prediction model. Besides, the expression of the genes in the model were validated using quantitative real-time PCR in clinical tissue specimens. Results The panel of DNA repair-related mRNA signature consisted of seven mRNAs: RFC4 (replication factor C subunit 4), ZWINT (ZW10 interacting kinetochore protein), UPF3B (UPF3B regulator of nonsense mediated mRNA decay), NCBP2 (nuclear cap binding protein subunit 2), ADA (adenosine deaminase), SF3A3 (splicing factor 3a subunit 3) and GTF2H1 (general transcription factor IIH subunit 1). On-line analysis of cBioPortal database found that the expression of the panel mRNA has a wide variation ranging from 7 to 10%. All the mRNAs were significantly upregulated in LC tissues compared to normal tissues (P
- Published
- 2021
- Full Text
- View/download PDF
5. Mediastinal follicular dendritic cell sarcoma: a rare, potentially under-recognized, and often misdiagnosed disease
- Author
-
You-Li Wu, Feng Wu, Cheng-Ping Xu, Guo-Lei Chen, Yu Zhang, Wei Chen, Xiao-Chu Yan, and Guang-Jie Duan
- Subjects
Follicular dendritic cell sarcoma ,Mediastinum ,Radiology ,Pathological diagnosis ,Prognosis ,Pathology ,RB1-214 - Abstract
Abstract Background Mediastinal follicular dendritic cell sarcoma (FDCS) is extremely rare. Due to potential under-recognization of this disease, it happens to be misdiagnosed, especially on core needle biopsy. We report 3 cases of mediastinal FDCS and provide a literature review to improve better understanding of the tumor and to reduce misdiagnosis. Methods Three cases of mediastinal FDCS in our clinic practice were studied, including their core needle biopsy and resected specimens, and those cases reported previously in English literature were retrieved and analyzed. Results The core needle biopsy of case 1 showed a tumor reminiscent of classical Hodgkin’s lymphoma (CHL), while the resected mass was finally diagnosed with FDCS combined with hyaline-vascular Castleman’s disease. Both the biopsy and resected tissue of case 2 were constitutive of the clear epithelioid cells with marked atypia. In both cases, definitive diagnoses were not made on core needle biopsy. In case 3, there were some areas morphologically similar to CHL, and some areas contained ovoid to spindle-shaped tumor cells with fascicular pattern. The analysis of 43 cases of mediastinal FDCS showed the age of patients were from 16 to 76 years old, the male to female ratio was 1.5:1, the maximal tumor diameters were 3–17 cm. 18 cases were underwent preoperative biopsy, whereas 15 (83.3%) of which were misdiagnosed initially, often as lymphoma. 32 patients had available follow-up data, the rates of recurrence, metastasis, and mortality were 12.5, 18.8 and 28.1%, respectively. Current limited data suggested no statistical differences between adverse prognosis and gender, age, tumor size, necrosis, or different therapeutics, respectively. Conclusions Mediastinal FDCS is a rare malignancy that has yet not been fully understood and been often misdiagnosed, particularly when making a diagnosis on core needle biopsy. Increased awareness of this enigmatic tumor is crucial to avoid diagnostic pitfalls.
- Published
- 2019
- Full Text
- View/download PDF
6. Mediastinal follicular dendritic cell sarcoma: a rare, potentially under-recognized, and often misdiagnosed disease
- Author
-
Wu, You-Li, Wu, Feng, Xu, Cheng-Ping, Chen, Guo-Lei, Zhang, Yu, Chen, Wei, Yan, Xiao-Chu, and Duan, Guang-Jie
- Published
- 2019
- Full Text
- View/download PDF
7. Primary pulmonary hyalinizing clear cell carcinoma with fusions of both EWSR1::CREM and IRF2:: NTRK3: report of a case with an aggressive behavior.
- Author
-
You-Li Wu, Feng Wu, Mian-Fu Cao, Yang Lan, Ming-Shan Du, Song-Tao Yu, Yan Wang, Xiao-Chu Yan, Xiu-Wu Bian, and Guang-Jie Duan
- Subjects
CELL fusion ,MUCOEPIDERMOID carcinoma ,FLUORESCENCE in situ hybridization ,RENAL cell carcinoma ,COMBINATION drug therapy ,GENETIC testing - Abstract
Primary pulmonary hyalinizing clear cell carcinoma (HCCC) is a rare salivary gland-type tumor newly recognized in recent years, with approximately 21 cases reported to date in the English literature, which constitutes a challenge in pathology diagnosis, particularly in small biopsy specimens. Here, we present a case of pulmonary HCCC diagnosed by computed tomography-guided percutaneous lung biopsy in a 70-year-old man's right lower lung. Although the morphology and immunophenotype of the tumor suggested the diagnosis of mucoepidermoid carcinoma, fluorescence in situ hybridization failed to reveal the rearrangement of MAML2 gene, which is characteristic of mucoepidermoid carcinoma. Instead, further molecular genetic testing showed that the tumor harbored a rare EWSR1::CREM fusion combined with a previously unreported IRF2::NTRK3 fusion. Pulmonary HCCC is commonly regarded as a low-grade malignant tumor with an indolent course, but this case has a different biological behavior, presenting extensive dissemination and metastases at the time of diagnosis, which expands our understanding of the prognosis of this tumor. The patient has had five cycles of combination chemotherapy and has been alive with the tumor for eight months. [ABSTRACT FROM AUTHOR]
- Published
- 2023
- Full Text
- View/download PDF
8. Identification of DNA repair-related genes predicting pathogenesis and prognosis for liver cancer
- Author
-
Qiliang Zhang, Min Liu, Wenjing Zhu, Yongchun Li, Meixing Yan, and Xiao Chu
- Subjects
Cancer Research ,RFC4 ,mRNA ,Nonsense-mediated decay ,Biology ,lcsh:RC254-282 ,03 medical and health sciences ,0302 clinical medicine ,Genetics ,medicine ,lcsh:QH573-671 ,Gene ,030304 developmental biology ,0303 health sciences ,lcsh:Cytology ,Biomarker ,Gene signature ,ZWINT ,TCGA ,medicine.disease ,Prognosis ,lcsh:Neoplasms. Tumors. Oncology. Including cancer and carcinogens ,Splicing factor 3a subunit 3 ,Oncology ,030220 oncology & carcinogenesis ,Cancer research ,General Transcription Factor IIH Subunit 1 ,Primary Research ,Liver cancer - Abstract
Background Liver cancer (LC) is one of the most fatal cancers throughout the world. More efficient and sensitive gene signatures that could accurately predict survival in LC patients are vitally needed to promote a better individualized and effective treatment. Material/methods 422 LC and adjacent normal tissues with both RNA-Seq and clinical data in TCGA were embedded in our study. Gene set enrichment analysis (GSEA) was applied to identify genes and hallmark gene sets that are more valuable for liver cancer therapy. Cox regression analysis was used to identify genes related to overall survival (OS) and build the prediction model. cBioPortal database was used to examine the alterations of the panel mRNA signature. ROC curves and Kaplan–Meier curves were used to validate the prediction model. Besides, the expression of the genes in the model were validated using quantitative real-time PCR in clinical tissue specimens. Results The panel of DNA repair-related mRNA signature consisted of seven mRNAs: RFC4 (replication factor C subunit 4), ZWINT (ZW10 interacting kinetochore protein), UPF3B (UPF3B regulator of nonsense mediated mRNA decay), NCBP2 (nuclear cap binding protein subunit 2), ADA (adenosine deaminase), SF3A3 (splicing factor 3a subunit 3) and GTF2H1 (general transcription factor IIH subunit 1). On-line analysis of cBioPortal database found that the expression of the panel mRNA has a wide variation ranging from 7 to 10%. All the mRNAs were significantly upregulated in LC tissues compared to normal tissues (P P-value Conclusions Our study demonstrated a mRNA signature including seven mRNA for prognosis prediction of LC. This panel gene signature provides a new criterion for accurate diagnosis and therapeutic target of LC.
- Published
- 2021
9. Predicting the Lung Squamous Cell Carcinoma Diagnosis and Prognosis Markers by Unique DNA Methylation and Gene Expression Profiles
- Author
-
Weiqing Wang, Hui Liu, Ming Xiang, Shaohua Wang, and Xiao Chu
- Subjects
Male ,Lung Neoplasms ,Biology ,03 medical and health sciences ,0302 clinical medicine ,Gene expression ,Biomarkers, Tumor ,Genetics ,Humans ,Protein Interaction Maps ,Endoplasmic Reticulum Chaperone BiP ,Molecular Biology ,Transcription factor ,Survival rate ,Gene ,Aged ,030304 developmental biology ,0303 health sciences ,POU domain ,Gene Expression Profiling ,PCDHA12 ,DNA Methylation ,Middle Aged ,Prognosis ,Gene Expression Regulation, Neoplastic ,Computational Mathematics ,Computational Theory and Mathematics ,030220 oncology & carcinogenesis ,Modeling and Simulation ,DNA methylation ,Carcinoma, Squamous Cell ,Cancer research ,SIM1 ,Female - Abstract
The early diagnosis of lung squamous cell carcinoma (LUSC) is difficult, causing an unsatisfactory prognosis. Therefore, the 5-year survival rate of LUSC is poor. This study aimed at screening the potential diagnostic and prognostic markers for LUSC. The data of LUSC gene expression profiles and DNA methylation were obtained from The Cancer Genome Atlas (TCGA) database; the differentially expressed genes (DEGs) and the differentially methylated genes (DMGs) were screened out by an independent t-test and Benjamini/Hochberg methods. Further, the classifiers of the gene expression and DNA methylation markers in LUSC were constructed. After that, diagnostic and prognostic markers in LUSC were analyzed by the protein-protein interaction (PPI) network. The DEGs and the DMGs from TCGA database of LUSC were screened out. After strict filtration, we identified three potential DMGs (POU domain, class 4, transcription factor 2 [POU4F2], EN1, single-minded homolog 1 [SIM1]) for early diagnosis and seven potential DEGs (G-protein coupled receptor 78 [GPR78], PCDHA5, myosin binding protein H [MYBPH], RTL3, KIAA0408, HSD3B2, PCDHA12) for prognosis of LUSC. The tumor-normal tissue classification model and prognosis model were validated in two independent datasets. In addition, the PPI network was constructed, including three DMGs and the five DEGs (GPR78, MYBPH, KIAA0408, HSD3B2, PCDHA12) of the seven DEGs. The potential DMGs (POU4F2, EN1, SIM1) and DEGs (GPR78, MYBPH, KIAA0408, HSD3B2, PCDHA12) for the diagnosis and prognosis of LUSC identified in this article are expected to be further applied in clinical practice of the treatment of LUSC.
- Published
- 2020
10. A brief report on incidence, radiographic feature and prognostic significance of brain MRI changes after anti-PD-1/PD-L1 therapy in advanced non-small cell lung cancer
- Author
-
Shengping Wang, Zhengfei Zhu, Yue Zhou, Xi Yang, Li Chu, Tiantian Guo, Yida Li, Qian Chu, Jie Hu, Xiao Chu, and Jianjiao Ni
- Subjects
Cancer Research ,medicine.medical_specialty ,Lung Neoplasms ,Immunology ,non-small cell lung cancer (NSCLC) ,B7-H1 Antigen ,Carcinoma, Non-Small-Cell Lung ,Immunology and Allergy ,Medicine ,Humans ,Cumulative incidence ,Lung cancer ,Adverse effect ,Stroke ,business.industry ,Incidence (epidemiology) ,Incidence ,Brain ,medicine.disease ,Prognosis ,Magnetic Resonance Imaging ,Hyperintensity ,Oncology ,Radiology ,business ,Encephalitis - Abstract
Neurologic immune-related adverse events (nirAEs) are uncommon but potentially lethal complications of immune checkpoint inhibitor (ICI) treatment. However, the incidence, radiographic features and prognostic significance of brain magnetic resonance imaging (MRI) changes after ICI treatment remain largely unknown. Consecutive patients with advanced non-small cell lung cancer (NSCLC) at three participating institutions receiving anti-PD-1/PD-L1 therapy from June 2017 to September 2020 were screened, and those who received brain MRI within 6 weeks before ICI initiation and at least one follow-up brain MRI after ICI treatment were included. Serial brain MRI images were independently reviewed by two experienced radiologists. With a median follow-up of 13.2 months, 27 (20.0%) of the 135 enrolled patients developed certain kind of brain MRI aberration. The 1-, 2- and 3-year cumulative incidence of brain MRI aberration was 17.1%, 36.3% and 52.2%, respectively. Brain MRI aberration indicative of stroke, mimicking typical white matter lesions and presenting as T2-hyperintensity suggestive of CNS vasculitis or encephalitis, was documented in 11, 9 and 4 patients, respectively. Patients with brain MRI aberration had higher clinical benefit rate (p = 0.030), longer progression-free survival (p = 0.015) and a tendency of improved overall survival (p = 0.054). Brain MRI aberrations developed after ICI treatment are not uncommon, and their manifestations vary a lot. Patients developing brain MRI aberrations tended to have better prognosis, which needed to be further investigated.
- Published
- 2021
11. Fatty acid receptor GPR120 promotes breast cancer chemoresistance by upregulating ABC transporters expression and fatty acid synthesis
- Author
-
Qiwei Wang, Bei Wang, Qiong Wu, Xiao Chu, Liang Xu, Xue Wang, Songbing He, Hui Wang, Min Jin, Qianjun Zhou, Yuting Gu, Yanyun Zhang, and Leizhen Zheng
- Subjects
0301 basic medicine ,Research paper ,GPR120 ,ATP-binding cassette transporter ,Receptors, G-Protein-Coupled ,Mice ,chemistry.chemical_compound ,Breast cancer ,0302 clinical medicine ,Antineoplastic Combined Chemotherapy Protocols ,Medicine ,Molecular Targeted Therapy ,Receptor ,Aged, 80 and over ,Fatty Acids ,NF-kappa B ,General Medicine ,Middle Aged ,Prognosis ,Neoadjuvant Therapy ,Gene Expression Regulation, Neoplastic ,Treatment Outcome ,ABC transporters ,Fatty acid synthesis ,030220 oncology & carcinogenesis ,Female ,RNA Interference ,Signal transduction ,Chemoresistance ,Signal Transduction ,Adult ,Breast Neoplasms ,Models, Biological ,General Biochemistry, Genetics and Molecular Biology ,03 medical and health sciences ,Downregulation and upregulation ,Animals ,Humans ,Protein kinase B ,Aged ,business.industry ,medicine.disease ,030104 developmental biology ,chemistry ,Drug Resistance, Neoplasm ,Cancer research ,ATP-Binding Cassette Transporters ,business ,Proto-Oncogene Proteins c-akt - Abstract
Background Chemoresistance is the major cause of neoadjuvant treatment failure in breast cancer patients. Despite recent progress, the mechanism underlying chemoresistance remains to be further defined. Methods Expression of G protein-coupled receptor 120 (GPR120) was analyzed by immunohistochemistry in the biopsies of primary breast cancer who subsequently underwent preoperative neoadjuvant chemotherapy. In vitro and in vivo loss- and gain-of -function studies were performed to reveal the effects and related mechanism of GPR120 signaling pathway in the chemoresistance of breast cancer cells. Findings We identified that GPR120, a receptor for long-chain fatty acids, was important for the acquisition of chemoresistance in breast cancer cells. We showed that GPR120 expression was positively associated with clinical response to neoadjuvant chemotherapy in patients. In breast cancer cells, GPR120 enhanced the de novo synthesis of fatty acids that served as GPR120 ligands to activate GPR120 signaling via a feedback mechanism. Upregulated GPR120 signaling rendered cells resistant to epirubicin-induced cell death by upregulating ABC transporters expression and thus decreasing the intracellular accumulation of epirubicin. Akt/NF-κB pathway was responsible for the GPR120-mediated expression of ABC transporters leading to modulation of the concentration of chemotherapeutic drugs in cells. The functional importance of GPR120 in chemoresistance was further validated using epirubicin-treated tumor xenografts, in which we showed that blockade of GPR120 signaling with AH7614 or GPR120-siRNA significantly compromised chemoresistance. Interpretation Our results highlight that GPR120 might be a promising therapeutic target for breast cancer chemoresistance. Fund National Natural Science Foundation of China, Ministry of Science and Technology of China, Program of Science and Technology Commission of Shanghai Municipality.
- Published
- 2019
12. Myocyte enhancer factor 2D promotes colorectal cancer angiogenesis downstream of hypoxia-inducible factor 1α
- Author
-
Zhi Yang, Cheng Qian, Matías A. Avila, Xing Zhong, Limei Liu, Juanjuan Shan, Hui Sun, Junyu Xiang, Li Su, Xiao-Chu Yan, Jun Chen, Chungang Liu, and Junjie Shen
- Subjects
Male ,0301 basic medicine ,CD31 ,Cancer Research ,Time Factors ,Angiogenesis ,0302 clinical medicine ,Tumor Microenvironment ,Promoter Regions, Genetic ,Mice, Inbred BALB C ,Neovascularization, Pathologic ,biology ,MEF2 Transcription Factors ,Middle Aged ,Prognosis ,Tumor Burden ,Gene Expression Regulation, Neoplastic ,Platelet Endothelial Cell Adhesion Molecule-1 ,Oncology ,Hypoxia-inducible factors ,030220 oncology & carcinogenesis ,Cytokines ,Female ,RNA Interference ,Signal transduction ,Colorectal Neoplasms ,HT29 Cells ,Platelet-derived growth factor receptor ,Signal Transduction ,Transcriptional Activation ,Mice, Nude ,Transfection ,03 medical and health sciences ,Paracrine Communication ,Biomarkers, Tumor ,Human Umbilical Vein Endothelial Cells ,medicine ,Animals ,Humans ,Tumor microenvironment ,Binding Sites ,Tumor hypoxia ,Cancer ,HCT116 Cells ,Hypoxia-Inducible Factor 1, alpha Subunit ,medicine.disease ,030104 developmental biology ,Culture Media, Conditioned ,Microvessels ,Cancer research ,biology.protein ,Tumor Hypoxia ,Caco-2 Cells - Abstract
Myocyte enhancer factor 2D (MEF2D) is involved in many aspects of cancer progression, including cell proliferation, invasion, and migration. However, little is known about the role of MEF2D in tumor angiogenesis. Using clinical specimens, colorectal cancer (CRC) cell lines and a mouse model in the present study, we found that MEF2D expression was positively correlated with CD31-positive microvascular density in CRC tissues. MEF2D promoted tumor angiogenesis in vitro and in vivo and induced the expression of proangiogenic cytokines in CRC cells. MEF2D was found to be a downstream effector of hypoxia-inducible factor (HIF)-1α in the induction of tumor angiogenesis. HIF-1α transactivates MEF2D expression by binding to the MEF2D gene promoter. These results demonstrate that the HIF-1α/MEF2D axis can serve as a therapeutic target for the treatment of CRC.
- Published
- 2017
13. ERAP2 Is Associated With Immune Infiltration and Predicts Favorable Prognosis in SqCLC.
- Author
-
Yang, Zhenlin, Tian, He, Bie, Fenglong, Xu, Jiachen, Zhou, Zheng, Yang, Junhui, Li, Renda, Peng, Yue, Bai, Guangyu, Tian, Yanhua, Chen, Ying, Liu, Lei, Fan, Tao, Xiao, Chu, Zheng, Yujia, Zheng, Bo, Wang, Jie, Li, Chunxiang, Gao, Shugeng, and He, Jie
- Subjects
BIOMARKERS ,IMMUNOSTAINING ,KILLER cells ,PEPTIDES ,PROGNOSIS - Abstract
Background: Immunotherapy has been proven effective among several human cancer types, including Squamous cell lung carcinoma (SqCLC). ERAP2 plays a pivotal role in peptide trimming of many immunological processes. However, the prognostic role of ERAP2 and its relationship with immune cell infiltration in SqCLC remains unclear. Methods: The differential expression of ERAP2 was identified via GEO and TCGA databases. We calculated the impact of ERAP2 on clinical prognosis using the Kaplan-Meier plotter. TIMER was applied to evaluate the abundance of immune cells infiltration and immune markers. SqCLC tissue microarrays containing 190 patients were constructed, and we performed immunohistochemical staining for ERAP2, CD8, CD47, CD68, and PD-L1 to validate our findings in public data. Results: In the GEO SqCLC database, ERAP2 was upregulated in patients with better survival (p=0.001). ERAP2 expression in SqCLC was significantly lower than that of matched normal samples (p<0.05) based on TCGA SqCLC data. Higher expression of ERAP2 was significantly associated with better survival in SqCLC patients from TCGA (p=0.007), KM-plotter (p=0.017), and our tissue microarrays (TMAs) (p=0.026). In univariate and multivariate Cox analysis of SqCLC TMAs, high ERAP2 expression was identified as an independent protective factor for SqCLC patients (Univariate Cox, HR=0.659, range 0.454-0.956, p<0.05. Multivariate Cox, HR=0.578, range 0.385-0.866, p<0.05). In TIMER, ERAP2 was positively correlated with several immune markers (CD274, p=1.27E-04; CD68, p=5.88E-08) and immune infiltrating cells (CD8
+ T cell, p=4.09E-03; NK cell, p=1.00E-04). In our cohort, ERAP2 was significantly correlated with CD8+ tumor-infiltrating lymphocytes (TILs) (p=0.0029), and patients with higher ERAP2 expression had a higher percentage of PD-L1 positive patients (p=0.049) and a higher CD8+ TILs level (p=0.036). Conclusions: For the first time, our study demonstrates that higher expression of ERAP2 is tightly associated with the immuno-supportive microenvironment and can predict a favorable prognosis in SqCLC. Meanwhile, ERAP2 may be a promising immunotherapeutic target for patients with SqCLC. [ABSTRACT FROM AUTHOR]- Published
- 2021
- Full Text
- View/download PDF
14. Aberrant fatty acid profile and FFAR4 signaling confer endocrine resistance in breast cancer
- Author
-
Yuting Gu, Qianjun Zhou, Changping Wu, Yanyun Zhang, Songbing He, Ying-Chun Xu, Qi Zhou, Min Jin, Qiong Wu, Fengchun Zhang, Hui Wang, Xue Wang, Bei Wang, Jingting Jiang, Xiaozhou He, Qing Li, and Xiao Chu
- Subjects
0301 basic medicine ,Cancer Research ,Receptors, G-Protein-Coupled ,Cohort Studies ,0302 clinical medicine ,Hormone receptor-positive breast cancer ,Middle Aged ,lcsh:Neoplasms. Tumors. Oncology. Including cancer and carcinogens ,Prognosis ,Tumor microenvironment ,Receptors, Estrogen ,Oncology ,030220 oncology & carcinogenesis ,Gas chromatography-mass spectrometry ,MCF-7 Cells ,Biomarker (medicine) ,Immunohistochemistry ,Female ,Endocrine resistance ,Signal Transduction ,medicine.drug ,Adult ,Antineoplastic Agents, Hormonal ,medicine.drug_class ,Breast Neoplasms ,lcsh:RC254-282 ,03 medical and health sciences ,Breast cancer ,FFAR4 ,Cell Line, Tumor ,medicine ,Humans ,RNA, Messenger ,Fatty acid receptor ,Fatty acids ,Aged ,business.industry ,Research ,Cancer ,Biomarker ,medicine.disease ,Tamoxifen ,030104 developmental biology ,Drug Resistance, Neoplasm ,Estrogen ,Cancer research ,Neoplasm Recurrence, Local ,business ,Hormone - Abstract
Background Evidence suggests that fatty acid receptor FFAR4 plays a tumor-promoting role in adipose tissue-adjacent malignancies, but its clinical relevance remains unexplored. Here, we investigated the clinical significance and underlying mechanisms of FFAR4 in hormone receptor-positive breast cancer (HRPBC). Methods FFAR4 expression was assessed by immunohistochemistry in an exploration cohort of 307 breast cancer cases collected from two independent institutes. Two public breast cancer microarray datasets served as validation cohorts. Gas chromatography-mass spectrometry was employed to identify FFAR4 ligands in normal and cancerous breast tissues. Survival analyses were performed in all cohorts and designated molecular subgroups. Mechanistic studies were performed in vitro in hormone receptor-positive breast cancer cell lines MCF-7 and T-47D. Results Aberrant FFAR4 expression and endogenous FFAR4 ligands were identified in breast cancer tissues, five FFAR4 ligands showed significantly elevated proportions in cancerous versus normal tissues. In the exploration cohort, FFAR4 was demonstrated as an independent prognostic factor for recurrences (HR: 2.183, 95% CI: 1.360–3.504, P = 0.001) and breast cancer-specific deaths (HR: 2.102, 95% CI: 1.173–3.766, P = 0.013) in HRPBC cases. In contrast, FFAR4 expression was not associated with prognosis in hormone receptor-negative cases. In the validation cohorts, FFAR4 mRNA levels were also observed to be associated with disease recurrence in estrogen receptor-positive cases, but not so in estrogen receptor-negative cases. FFAR4 activation by endogenous ligands and a synthetic ligand TUG891 significantly dampened tamoxifen’s efficacy on HRPBC cells, whereas FFAR4 knockdown or antagonist AH7614 abrogated this effect. Furthermore, FFAR4-induced tamoxifen resistance was dependent on ERK and AKT pathways in HRPBC. Conclusions Our results establish a novel role of FFAR4 and its ligands in the complicated interactions between tissue lipid profile and cancer biology. FFAR4 signaling confers tamoxifen resistance in HRPBC cell line and FFAR4 expression can serve as a prognostic biomarker for tamoxifen-treated HRPBC patients. FFAR4 may serve as a potential target for anti-breast cancer therapies, especially in endocrine resistant cases. Electronic supplementary material The online version of this article (10.1186/s13046-019-1040-3) contains supplementary material, which is available to authorized users.
- Published
- 2019
15. Mediastinal follicular dendritic cell sarcoma: a rare, potentially under-recognized, and often misdiagnosed disease
- Author
-
Xiao-Chu Yan, Yu Zhang, Guangjie Duan, Cheng-Ping Xu, You-Li Wu, Wei Chen, Feng Wu, and Guo-Lei Chen
- Subjects
0301 basic medicine ,Adult ,Male ,Pathology ,medicine.medical_specialty ,Histology ,Adolescent ,Dendritic Cell Sarcoma, Follicular ,Malignancy ,Pathology and Forensic Medicine ,Metastasis ,03 medical and health sciences ,Pathological diagnosis ,Young Adult ,0302 clinical medicine ,Drug Therapy ,Biopsy ,lcsh:Pathology ,medicine ,Atypia ,Humans ,Aged ,medicine.diagnostic_test ,Radiotherapy ,business.industry ,Research ,Mediastinum ,General Medicine ,Middle Aged ,medicine.disease ,Prognosis ,Lymphoma ,030104 developmental biology ,medicine.anatomical_structure ,030220 oncology & carcinogenesis ,Follicular dendritic cell sarcoma ,Female ,Biopsy, Large-Core Needle ,business ,Radiology ,Tomography, X-Ray Computed ,Epithelioid cell ,lcsh:RB1-214 - Abstract
Background Mediastinal follicular dendritic cell sarcoma (FDCS) is extremely rare. Due to potential under-recognization of this disease, it happens to be misdiagnosed, especially on core needle biopsy. We report 3 cases of mediastinal FDCS and provide a literature review to improve better understanding of the tumor and to reduce misdiagnosis. Methods Three cases of mediastinal FDCS in our clinic practice were studied, including their core needle biopsy and resected specimens, and those cases reported previously in English literature were retrieved and analyzed. Results The core needle biopsy of case 1 showed a tumor reminiscent of classical Hodgkin’s lymphoma (CHL), while the resected mass was finally diagnosed with FDCS combined with hyaline-vascular Castleman’s disease. Both the biopsy and resected tissue of case 2 were constitutive of the clear epithelioid cells with marked atypia. In both cases, definitive diagnoses were not made on core needle biopsy. In case 3, there were some areas morphologically similar to CHL, and some areas contained ovoid to spindle-shaped tumor cells with fascicular pattern. The analysis of 43 cases of mediastinal FDCS showed the age of patients were from 16 to 76 years old, the male to female ratio was 1.5:1, the maximal tumor diameters were 3–17 cm. 18 cases were underwent preoperative biopsy, whereas 15 (83.3%) of which were misdiagnosed initially, often as lymphoma. 32 patients had available follow-up data, the rates of recurrence, metastasis, and mortality were 12.5, 18.8 and 28.1%, respectively. Current limited data suggested no statistical differences between adverse prognosis and gender, age, tumor size, necrosis, or different therapeutics, respectively. Conclusions Mediastinal FDCS is a rare malignancy that has yet not been fully understood and been often misdiagnosed, particularly when making a diagnosis on core needle biopsy. Increased awareness of this enigmatic tumor is crucial to avoid diagnostic pitfalls.
- Published
- 2019
16. Perivascular Epithelioid Cell Tumor of Urinary Bladder.
- Author
-
Wu, You-li, Lang, Lang, Ma, Qiang, Wu, Feng, Zhang, Yu, Chen, Wei, Yan, Xiao-chu, and Duan, Guang-jie
- Subjects
CELL tumors ,FLUORESCENCE in situ hybridization ,BLADDER cancer - Abstract
Objectives: To review the clinicopathologic features of perivascular epithelioid cell tumor (PEComa) of the urinary bladder.Methods: Seven cases of bladder PEComa were studied by light microscopy, immunohistochemistry, and fluorescence in situ hybridization (FISH).Results: In our 7 cases, 5 patients were female and 2 were male, with ages between 26 and 78 years. Patients presented with hematuria and recurrent abdominal discomfort as the main clinical symptoms. Microscopically, the epithelioid and spindle-shaped tumor cells with clear to granular eosinophilic cytoplasm were arranged in fascicular, acinar, or nested patterns. The tumor cells were positive for HMB45, melan-A, and SMA, but no TFE3 gene rearrangement was detected in any of the 7 samples by FISH. The analysis of all 35 cases from the literature and ours showed a patient age range from 16 to 78 years (mean age, 39 years), a male-to-female ratio of 1:1.3, maximal tumor diameters from 0.6 to 18.8 cm (mean, 4.5 cm). With a mean follow-up of 27 months, the recurrence, metastasis, and mortality rates were 10.7%, 10.7%, and 7.1%, respectively.Conclusions: Bladder PEComa is extremely rare, remains a diagnostic challenge, and needs more attention. Strengthening the understanding of this tumor will improve diagnostic accuracy. [ABSTRACT FROM AUTHOR]- Published
- 2021
- Full Text
- View/download PDF
17. Expression of hypoxia-inducible factor prolyl hydroxylase 3 HIFPH3 in human non-small cell lung cancer (NSCLC) and its correlation with prognosis
- Author
-
Xiao Chu, Hui Liu, Cheng-Chu Zhu, and Jiao-Chen Wang
- Subjects
CD31 ,Adult ,Male ,Cancer Research ,medicine.medical_specialty ,Pathology ,Lung Neoplasms ,Epidemiology ,non-small cell lung cancer (NSCLC) ,Respiratory Mucosa ,Metastasis ,Hypoxia-Inducible Factor-Proline Dioxygenases ,Carcinoma, Non-Small-Cell Lung ,Carcinoma ,medicine ,Humans ,Lung ,Aged ,Aged, 80 and over ,business.industry ,Public Health, Environmental and Occupational Health ,Middle Aged ,medicine.disease ,Prognosis ,Platelet Endothelial Cell Adhesion Molecule-1 ,medicine.anatomical_structure ,Oncology ,Hypoxia-inducible factors ,Lymphatic Metastasis ,Microvessels ,cardiovascular system ,Immunohistochemistry ,Histopathology ,Female ,business - Abstract
Purpose: To investigate the expression of hypoxia-inducible factor prolyl hydroxylase 3 (HIFPH3) in non-small cell lung cancer (NSCLC) and explore the correlation of HIFPH3 expression with lymph node metastasis and microvessel density (MVD). Materials and Methods: A total of 73 cases of NSCLC specimens, 24 cases of paracancerous tissues, and 20 normal pulmonary tissues were collected for HIFPH3 and CD31 immunohistochmical (IHC) study. Microvessel density (MVD) of the NSCLC tissues was also determined based on the expression of CD31. Results: The expression of HIFPH3 in carcinoma tissue was statistically higher than para-cancerous and normal pulmonary tissues (χ 2 =48.806, p
- Published
- 2014
18. miR-145 suppresses the proliferation, invasion and migration of NSCLC cells by regulating the BAX/BCL-2 ratio and the caspase-3 cascade.
- Author
-
Pan, Yi, Ye, Conglin, Tian, Qingshan, Yan, Songxin, Zeng, Xiaoping, Xiao, Chu, Wang, Lingyun, and Wang, Hongmei
- Subjects
MICRORNA ,CASPASES ,NON-small-cell lung carcinoma ,BAX protein ,GENE expression ,PROGNOSIS - Abstract
Although microRNA (miR)-145 has been identified to be a tumor suppressor in various types of tumor, it promotes the progression of non-small cell lung cancer (NSCLC). However, the precise underlying molecular mechanism of its action remains unclear. The present study investigated the effects of miR-145 on the proliferation, invasion, metastasis and apoptosis of the NSCLC A549 cell line and the underlying molecular mechanism of its action. In vitro cell proliferation, invasion, migration and apoptosis assays were employed, and the expression levels of matrix metalloproteinase (MMP)-2, MMP-9, B-cell lymphoma 2 (Bcl-2), Bcl-2-associated X protein (Bax), caspase-3and poly(ADP-ribose) polymerase (PARP) were evaluated by western blot analysis. The results demonstrated that ectopic expression of miR-145 inhibited the proliferation, invasion and migration of A549 cells, but promoted the apoptosis of A549 cells. Western blot analysis indicated that increased miR-145 levels led to a marked decrease in the expression of MMP-2, MMP-9 and Bcl-2. Upregulation of miR-145 expression increased the expression of Bax, thus increasing the Bax/Bcl-2 ratio. Additionally, the results indicated that miR-145 over expression promoted the cleavage of caspase-3 and PARP. Taken together, these results indicated that miR-145 suppresses the proliferative, invasive and migratory ability of A549 cells. Additionally, miR-145 upregulation induced apoptosis of A549 cells possibly by decreasing MMP-2 and MMP-9 expression, the Bax/Bcl-2 ratio and the activity of the caspase-3 cascade. [ABSTRACT FROM AUTHOR]
- Published
- 2018
- Full Text
- View/download PDF
19. [Characteristic and clinicopathologic significance of lymphangiogenesis in colorectal cancer]
- Author
-
Jiang-hong, Mou, Xiao-chu, Yan, Zeng-peng, Li, Dong, Wang, Guang-jie, Duan, De-bing, Xiang, Hua-liang, Xiao, and Qin-hong, Zhang
- Subjects
Adult ,Aged, 80 and over ,Male ,Adenocarcinoma ,Middle Aged ,Prognosis ,Survival Rate ,Ki-67 Antigen ,Lymphatic Metastasis ,Humans ,Female ,Endothelium, Vascular ,Lymphangiogenesis ,Colorectal Neoplasms ,Aged ,Follow-Up Studies ,Lymphatic Vessels - Abstract
To investigate the distribution patterns and proliferative activity of lymphatic vessels in colorectal carcinomas (CRC) and their relationship with tumor metastasis and disease prognosis.The microlymphatic density (MLD) and microvascular density in tumoral and non-tumoral areas of 96 cases of CRC were evaluated by immunohistochemistry, using monoclonal antibodies for podoplanin and CD34 respectively. The Ki-67 expression of the lymphatic and blood vessels was detected by double-labeling immunohistochemistry. The relationship between MLD and clinicopathologic features and prognosis was analyzed.The lymph vessels at central and superficia1 portions of CRC often had a reticular architecture with numerous tiny and ill-defined lumina, while those at the tumor borders had large and open lumina. The MLD at tumor borders (51.2 +/- 25.5) was significantly higher than that in normal colorectal mucosa (29.4 +/- 9.0) and other portions of CRC (P0.01). The Ki-67 labeling index of the lymphatic lining cells at tumor borders (0.23 +/- 0.17) was significantly higher than that in other portions of CRC (P0.05). The MLD significantly correlated with lymphatic involvement by tumor cells, regional lymph node metastasis and distant metastasis (P0.01). The 5-year survival rate was also significantly lower in patients with high MLD (P0.05).Neolymphatic vessels are commonly seen in CRC, especially at tumor borders. High MLD at tumor borders is associated with metastasis. The detection of MLD at tumor borders may thus be useful in predicting lymph node metastasis and prognosis in patients with CPC.
- Published
- 2005
20. [Clinical significance of survivin expression in colorectal cancer and its relationship with cell apoptosis and angiogenesis]
- Author
-
Jing, Yang, Feng-Xuan, Liu, Xiao-Chu, Yan, Guang-You, He, and Li-Mei, Liu
- Subjects
Adult ,Aged, 80 and over ,Male ,Vascular Endothelial Growth Factor A ,Lung Neoplasms ,Neovascularization, Pathologic ,Rectal Neoplasms ,Survivin ,Liver Neoplasms ,Apoptosis ,Middle Aged ,Prognosis ,Inhibitor of Apoptosis Proteins ,Neoplasm Proteins ,Survival Rate ,Lymphatic Metastasis ,Colonic Neoplasms ,Humans ,Female ,Microtubule-Associated Proteins ,Aged ,Follow-Up Studies ,Neoplasm Staging - Abstract
Expression of survivin, an apoptosis suppressor gene, in colorectal cancer(CRC), and its relationship with pathologic factors, cell apoptosis, and angiogenesis are unclear. This study aimed to investigate the effect of survivin on cell apoptosis, and its relation with angiogenesis, and to further explore the effects of survivin on development and prognosis of CRC.Protein expression of survivin, and vascular endothelial growth factor (VEGF) in 91 specimens of CRC was detected by immunohistochemistry, apoptosis index (AI) of tumor cells was detected by TUNEL method.Positive rate of survivin in CRC with distant metastasis was 56.0% (14/25), significantly higher than that in CRC without metastasis (48.5%, 32/66) (P0.05); and that in 5-year survival patients(42.9%,30/70) was lower than that in patients died within 5 years (76.2%,16/21) (P0.01). The average survival time of patients with positive expression of survivin was 91.3 months, and that of patients with negative expression of survivin was 116.4 months; 5-year survival rate of the former (65.2%, 30/46) was significantly lower than that of the latter (88.9%, 40/45) (P0.01). The average AI of patients with positive expression of survivin was lower than that of patients with negative expression of survivin [(0.74+/-0.19)% vs. (1.07+/-0.24)%, P0.01]; the expression of survivin significantly correlated with that of VEGF (pearson: 0.721).Survivin may promote metastasis, and affect prognosis of CRC through inhibiting cell apoptosis, and regulating angiogenesis of CRC.
- Published
- 2005
21. Impact and Predictive Value of Prostate Weight on the Outcomes of Nerve Sparing Laparoscopic Radical Prostatectomy in Patients with Low Risk Prostate Cancer.
- Author
-
Dong-Gen Jiang, Chu-Tian Xiao, Yun-Hua Mao, Jian-Guang Qiu, Jie Si-tu, Min-Hua Lu, Xin Gao, Jiang, Dong-Gen, Xiao, Chu-Tian, Mao, Yun-Hua, Qiu, Jian-Guang, Si-Tu, Jie, Lu, Min-Hua, and Gao, Xin
- Subjects
- *
PROSTATECTOMY , *GLEASON grading system , *PROSTATE , *PROSTATE cancer , *BLOOD loss estimation , *PROSTATE-specific antigen , *RANK correlation (Statistics) , *ANTHROPOMETRY , *IMPOTENCE , *LAPAROSCOPY , *PROSTATE tumors , *RISK assessment , *SURGICAL complications , *THERAPEUTICS , *URINARY incontinence , *TREATMENT effectiveness , *PREDICTIVE tests , *RETROSPECTIVE studies - Abstract
Purpose: To investigate the impact of prostate weight on outcomes of nerve sparing laparoscopic radical prosta-tectomy (LRP) and assess its predictive value on postoperative continence and potency recovery.Materials and Methods: We conducted a retrospective study on the clinical data of 165 patients with low risk prostate cancer (PCa) who underwent nerve sparing LRP. All the patients included had normal preoperative uri-nary and sexual function. The association of prostate weight with perioperative data was assessed using Spearman correlation coefficient. Univariate and multivariate Cox regression analyses were employed to identify prognostic predictors for continence and potency recovery.Results: Increased prostate weight was significantly associated with older age, higher prostate-specific antigen (PSA), lower biopsy and pathological T stage and Gleason score, longer operative time, and higher estimated blood loss (P < .05). The continence rates at the 3rd, 6th, and 12th month after surgery were 63.6% (105/165), 87.9% (145/165), and 95.8% (158/165); and the potency rates were 44.8% (74/165), 62.4% (103/165) and 77.6% (128/165), respectively. Furthermore, multivariate Cox analysis showed that patient age (HR = 0.52, 95% CI: 0.35- 0.76) and prostate weight (HR = 0.54, 95% CI: 0.34-0.86) were independent predictors for continence recovery, while only patient age (HR = 0.66, 95% CI: 0.45-0.96) could independently predict potency recovery.Conclusion: Larger prostate size was correlated with older age, higher PSA, lower tumor stage and grade, longer operative time, and more intraoperative blood loss in low risk PCa patients. Increased prostate weight may inde-pendently predict poor continence recovery after nerve sparing LRP. [ABSTRACT FROM AUTHOR]- Published
- 2019
- Full Text
- View/download PDF
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.